CAPR - カプリコ―ル・セラピュ―ティクス （Capricor Therapeutics Inc.）

Company to Host Conference Call, August 10, 2022, at 4:30 p.m. ET Company to Host Conference Call, August 10, 2022, at 4:30 p.m. ET

Capricor Therapeutics (CAPR) announced one-year results from a mid-stage open-label extension study on Monday to indicate that its lead asset CAP-1002 led to statistically…

SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. Linda Marbán, CEO of Capricor, will present at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022 in Miami, Florida. Please see additional presentation details below:

Capricor Therapeutics, Inc. (NASDAQ:NASDAQ:CAPR) Q1 2022 Earnings Conference Call May 10, 2022, 16:30 ET Company Participants Anthony Bergmann - CFO & Corporate Treasurer Linda Marban -…

Capricor Therapeutics press release (CAPR): Q1 GAAP EPS of -$0.32.The company believes that based on the current operating plan and financial resources, the company expects that…

Company to Host Conference Call, May 10, 2022, at 4:30 p.m. ET Company to Host Conference Call, May 10, 2022, at 4:30 p.m. ET

U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping around 150 points on Monday. The Dow traded down 0.43% to 34,709.71 while the NASDAQ rose 0.42% to 14,228.48. The S&P also fell, dropping, 0.02% to 4,542.04. Also check this: Alphabet And 3 Other Stocks Sold By Insiders Leading and Lagging Sectors Consumer discretionary shares jumped by 1.6% on Monday. Meanwhile, top gainers in the sector included Kaixin Auto Holdings (NASDAQ: KXIN ), up 31% and Newegg Commerce, Inc. (NASDAQ: NEGG ) up 41%. In trading on Monday, energy shares fell 2.8%. Top Headline Science Applications International Corp (NYSE: SAIC ) reported better-than-expected earnings for its fourth quarter. SAIC reported fourth-quarter FY22 revenue growth of 4% year-over-year to $1.78 billion and +1.4% organic, beating the consensus of $1.77 billion. Adjusted EPS of $1.50 beat the consensus of $1.23. SAIC sees revenue of $7.35 billion-$7.55 billion, lower than the consensus of $7.61 billion. It expects an Adjusted EPS of $6.80 -$7.10 …

Capricor Therapeutics Inc (NASDAQ: CAPR ) announced topline data from its Phase 2 INSPIRE study evaluating a single-dose intravenous infusion of CAP-1002 for hospitalized COVID-19 patients. Capricor said that the trial met its primary objective of safety. All efficacy endpoints were exploratory as the study was not powered to detect treatment differences. In the study of 63 randomized patients, 31% were admitted to the ICU before … Full story available on Benzinga.com

A phase 2 trial of Capricor Therapeutics (CAPR) COVID-19 treatment CAP-1002 met its primary objective of safety.

In its Q4 FY21 earnings press release , Capricor Therapeutics Inc (NASDAQ: CAPR ) said it had halted work on the exosome-based jab due to the "current availability of vaccines for" COVID-19, Capricor said. Instead, the Company will focus its resources on CAP-1002 and announce the Lancet publication of Phase 2 trial results for the Duchenne muscular dystrophy (DMD) treatment CAP-1002. According to the Lancet publication, after … Full story available on Benzinga.com

NEW YORK , Jan. 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SOFI, BBIG, DIDI, CAPR, and PIXY. … Full story available on Benzinga.com

Capricor Therapeutics (CAPR) soars 12.4% premarket after entering into a partnership with Nippon Shinyaku Co., Ltd., a Japanese pharmaceutical company, for the exclusive

Rallybio (NASDAQ:RLYB) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability. Analyst Ratings This is a breakdown of recent ratings and recommmendations for Rallybio and Capricor Therapeutics, […]

Global Muscular Dystrophy Treatment Market has potentials to grow as the most influential market worldwide as it has been playing a noteworthy role in imprinting positive impacts on the international economy. The Global Muscular Dystrophy Treatment Market Report offers vital